Literature DB >> 25738652

Targeting FoxM1 inhibits proliferation, invasion and migration of nasopharyngeal carcinoma through the epithelial‑to-mesenchymal transition pathway.

Chao Yu1, Lili Chen1, Lin Yie1, Lei Wei1, Taoyu Wen1, Yanan Liu1, Hongyan Chen1.   

Abstract

High expression levels of the forkhead box M1 (FoxM1) transcription factor are associated with metastasis and poor prognosis of malignancies. However, little is known concerning its function in nasopharyngeal carcinoma (NPC). The present study aimed to investigate the impact of FoxM1 inhibition on the migration and invasion of NPC cells and the potential mechanisms. The effects of FoxM1 inhibitor treatment and FoxM1 silencing on the proliferation, migration and invasion of NPC CNE-1 and CNE-2 cells were examined by CCK-8, Transwell migration/invasion and colony formation assays. The effects of stable FoxM1 silencing on the growth and lung metastasis of implanted NPC were evaluated. The relative levels of FoxM1, zinc finger E-box binding homeobox 2 (ZEB2), Snail2 and E-cadherin in the different groups of NPC cells and tumors were determined by quantitative real-time PCR, western blotting and immunohistochemical assays. Treatment with thiostrepton, FoxM1 inhibitor, significantly reduced the survival of NPC cells. Treatment with thiostrepton and/or knockdown of FoxM1 inhibited the anchorage-independent proliferation, migration and invasion of NPC cells. Inhibition of FoxM1 also increased the relative levels of E-cadherin, but reduced ZEB2 and Snail2 expression in NPC cells. Stable FoxM1 silencing inhibited the growth and lung metastasis of implanted NPC in vivo, which was associated with increased levels of E-cadherin, but decreased ZEB2 and Snail2 expression in the NPC tumors. In conclusion, our data clearly indicate that knockdown of FoxM1 inhibited the growth and metastasis of human NPC by modulating epithelial-to-mesenchymal transition (EMT), and FoxM1 may be a potential target for the intervention of NPC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25738652     DOI: 10.3892/or.2015.3834

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  15 in total

1.  FOXM1 and FOXQ1 Are Promising Prognostic Biomarkers and Novel Targets of Tumor-Suppressive miR-342 in Human Colorectal Cancer.

Authors:  Wenhao Weng; Yoshinaga Okugawa; Shusuke Toden; Yuji Toiyama; Masato Kusunoki; Ajay Goel
Journal:  Clin Cancer Res       Date:  2016-05-09       Impact factor: 12.531

2.  A preclinical evaluation of thiostrepton, a natural antibiotic, in nasopharyngeal carcinoma.

Authors:  Yen-Bin Hsu; Ming-Chin Lan; Yu-Lun Kuo; Chi-Ying F Huang; Ming-Ying Lan
Journal:  Invest New Drugs       Date:  2019-04-16       Impact factor: 3.850

3.  Effects of thiostrepton alone or in combination with selumetinib on triple-negative breast cancer metastasis.

Authors:  Funda Demirtas Korkmaz; Irem Dogan Turacli; Guldal Esendagli; Abdullah Ekmekci
Journal:  Mol Biol Rep       Date:  2022-09-12       Impact factor: 2.742

4.  MiR-214 inhibits cell migration, invasion and promotes the drug sensitivity in human cervical cancer by targeting FOXM1.

Authors:  Jian-Mei Wang; Bao-Hui Ju; Cai-Jun Pan; Yan Gu; Meng-Qi Li; Li Sun; Yan-Ying Xu; Li-Rong Yin
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

5.  Glycogen synthase kinase-3β inhibits tubular regeneration in acute kidney injury by a FoxM1-dependent mechanism.

Authors:  Sonali Sinha; Nidhi Dwivedi; James Woodgett; Shixin Tao; Christianna Howard; Timothy A Fields; Abeda Jamadar; Reena Rao
Journal:  FASEB J       Date:  2020-08-19       Impact factor: 5.191

6.  FoxM1 promotes epithelial-mesenchymal transition, invasion, and migration of tongue squamous cell carcinoma cells through a c-Met/AKT-dependent positive feedback loop.

Authors:  Huiling Yang; Li Wen; Mingling Wen; Tao Liu; Lisheng Zhao; Bo Wu; Yuyu Yun; Wenchao Liu; Hao Wang; Yu Wang; Ning Wen
Journal:  Anticancer Drugs       Date:  2018-03       Impact factor: 2.248

7.  FoxM1 is an independent poor prognostic marker and therapeutic target for advanced Middle Eastern breast cancer.

Authors:  Abdul Khalid Siraj; Poyil Pratheeshkumar; Sandeep Kumar Parvathareddy; Zeeshan Qadri; Saravanan Thangavel; Saeeda Ahmed; Fouad Al-Dayel; Asma Tulbah; Dahish Ajarim; Khawla S Al-Kuraya
Journal:  Oncotarget       Date:  2018-04-03

8.  Expression of FoxM1 and the EMT-associated protein E-cadherin in gastric cancer and its clinical significance.

Authors:  Jing Zhang; Xiao-Yu Chen; Ke-Jian Huang; Wei-Dong Wu; Tao Jiang; Jun Cao; Li-Sheng Zhou; Zheng-Jun Qiu; Chen Huang
Journal:  Oncol Lett       Date:  2016-07-28       Impact factor: 2.967

9.  Foxj2 overexpression is associated with poor prognosis, progression, and metastasis in nasopharyngeal carcinoma.

Authors:  Ying Shan; Tao Chang; Si Shi; Mingming Tang; Lili Bao; Li Li; Bo You; Yiwen You
Journal:  Onco Targets Ther       Date:  2017-07-24       Impact factor: 4.147

10.  Inhibition of Wnt3a/FOXM1/β-Catenin Axis and Activation of GSK3β and Caspases are Critically Involved in Apoptotic Effect of Moracin D in Breast Cancers.

Authors:  Sung Min Hwang; Hyo-Jung Lee; Ji Hoon Jung; Deok Yong Sim; Jisung Hwang; Ji Eon Park; Bum Sang Shim; Sung-Hoon Kim
Journal:  Int J Mol Sci       Date:  2018-09-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.